Natural Health Trends Corp

Natural Health Trends Corp(NHTC)股票分析

$0.764

-0.076 (-9.99%)收盤時

Loading chart…
最高
0.870
開盤
0.856
成交量加權均價
0.78
成交量
129.04K
市值
81.08M
最低
0.700
成交金額
100.39K
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

Natural Health Trends Corp. is a direct-selling and e-commerce company. The Company offers a line of NHT Global branded products in categories which include wellness, herbal, beauty, lifestyle and at-home tests. Its wellness products are formulated and designed to meet specific wellness goals, which include nutrition for joint health, antioxidant support, digestive health, heart health, vision health, immune support and cellular health. Its beauty product line includes age-defying and hydrating cleansers, creams, lotions, serums and toners to moisturize, protect and improve the appearance of skin. Its lifestyle products support active, physical and healthy lifestyles, including weight management, and energy-enhancing supplements. Its wellness products include Triotein, Cluster X2, ReStor Silver, and Glucosamine 2200. Its herbal products include LivaPro, Cordyceps Mycelia CS-4, and RespFactor. Its beauty products include Skindulgence Essence Gel, Floraeda Toner and Primer.

AI 分析 of Natural Health Trends Corp (NHTC)

持有

Natural Health Trends Corp (NHTC) is not a strong buy at this moment due to its current price of 0.7642, which is close to its 52-week low of 0.70, indicating a lack of upward momentum. The RSI is at 38.098, suggesting that the stock is nearing oversold territory but has not yet shown signs of a reversal. Additionally, the forward P/E ratio is 13.44, which is reasonable, but the company has reported a significant year-to-date change of -75.19%, reflecting ongoing challenges in revenue generation and profitability. The main risk is the declining net income, which has been negative for the last three quarters, with the latest reported net income of -232,000 USD in Q3 2026.

估值指標

Natural Health Trends Corp(NHTC)目前預期本益比為 13.44,5 年平均預期本益比為 2.59。

預期本益比

高估
5 年均值 P/E
2.59
目前P/E
13.44
高估
8.48
低估
-3.30

預期 EV/EBITDA

嚴重低估
5 年均值 EV/EBITDA
0.00
目前EV/EBITDA
0.00
高估
0.00
低估
0.00

預期股價營收比

嚴重低估
5 年均值 P/S
0.00
目前P/S
0.00
高估
0.00
低估
0.00

Alphio AI 對 NHTC 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%NHTC

$5.32

情境價格

基

基準

基準 · 50%NHTC

$4.76

情境價格

悲

悲觀

悲觀 · 25%NHTC

$4.39

情境價格

事件時間軸

2026-02-17 (ET)

16:50:00

Natural Health Repurchases Shares from George K. Broady Family for $5.9M

2026-02-04 (ET)

09:10:00

Natural Health Trends Corp Q4 Revenue at $9.7M

2025-11-05 (ET)

09:03:54

Natural Health Trends announces Q3 EPS of 4 cents compared to 0 cents in the previous year.

2025-07-30 (ET)

09:02:00

Natural Health Trends reports Q2 EPS 0c vs 2c last year

2025-04-30 (ET)

09:07:07

Natural Health Trends reports Q1 EPS 1c vs 2c last year

資訊

NHTC 常見問題 —— 由 Alphio AI 解答

Natural Health Trends Corp. is a direct-selling and e-commerce company. The Company offers a line of NHT Global branded products in categories which include wellness, herbal, beauty, lifestyle and at-home tests. Its wellness products are formulated and designed to meet specific wellness goals, which include nutrition for joint health, antioxidant support, digestive health, heart health, vision health, immune support and cellular health. Its beauty product line includes age-defying and hydrating cleansers, creams, lotions, serums and toners to moisturize, protect and improve the appearance of skin. Its lifestyle products support active, physical and healthy lifestyles, including weight management, and energy-enhancing supplements. Its wellness products include Triotein, Cluster X2, ReStor Silver, and Glucosamine 2200. Its herbal products include LivaPro, Cordyceps Mycelia CS-4, and RespFactor. Its beauty products include Skindulgence Essence Gel, Floraeda Toner and Primer. It operates in the Consumer Cyclicals sector (WHOLESALE-MISCELLANEOUS NONDURABLE GOODS industry).

Natural Health Trends Corp (NHTC) is not a strong buy at this moment due to its current price of 0.7642, which is close to its 52-week low of 0.70, indicating a lack of upward momentum. The RSI is at 38.098, suggesting that the stock is nearing oversold territory but has not yet shown signs of a reversal. Additionally, the forward P/E ratio is 13.44, which is reasonable, but the company has reported a significant year-to-date change of -75.19%, reflecting ongoing challenges in revenue generation and profitability. The main risk is the declining net income, which has been negative for the last three quarters, with the latest reported net income of -232,000 USD in Q3 2026.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易